AGL vs. PGNY, PRVA, PINC, SYNH, OPCH, PACS, HIMS, GH, FTRE, and NHC
Should you be buying agilon health stock or one of its competitors? The main competitors of agilon health include Progyny (PGNY), Privia Health Group (PRVA), Premier (PINC), Syneos Health (SYNH), Option Care Health (OPCH), PACS Group (PACS), Hims & Hers Health (HIMS), Guardant Health (GH), Fortrea (FTRE), and National HealthCare (NHC). These companies are all part of the "medical" sector.
agilon health (NYSE:AGL) and Progyny (NASDAQ:PGNY) are both mid-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, community ranking, media sentiment, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.
Progyny received 39 more outperform votes than agilon health when rated by MarketBeat users. Likewise, 75.21% of users gave Progyny an outperform vote while only 50.52% of users gave agilon health an outperform vote.
In the previous week, Progyny had 5 more articles in the media than agilon health. MarketBeat recorded 8 mentions for Progyny and 3 mentions for agilon health. Progyny's average media sentiment score of 0.53 beat agilon health's score of 0.20 indicating that Progyny is being referred to more favorably in the news media.
agilon health has a beta of 0.6, indicating that its stock price is 40% less volatile than the S&P 500. Comparatively, Progyny has a beta of 1.46, indicating that its stock price is 46% more volatile than the S&P 500.
agilon health currently has a consensus target price of $9.10, indicating a potential upside of 37.25%. Progyny has a consensus target price of $42.40, indicating a potential upside of 45.91%. Given Progyny's stronger consensus rating and higher probable upside, analysts clearly believe Progyny is more favorable than agilon health.
Progyny has a net margin of 5.53% compared to agilon health's net margin of -5.67%. Progyny's return on equity of 11.61% beat agilon health's return on equity.
Progyny has lower revenue, but higher earnings than agilon health. agilon health is trading at a lower price-to-earnings ratio than Progyny, indicating that it is currently the more affordable of the two stocks.
94.9% of Progyny shares are owned by institutional investors. 3.2% of agilon health shares are owned by insiders. Comparatively, 12.3% of Progyny shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Summary
Progyny beats agilon health on 17 of the 18 factors compared between the two stocks.
Get agilon health News Delivered to You Automatically
Sign up to receive the latest news and ratings for AGL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AGL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
agilon health Competitors List
Related Companies and Tools
